Raywatt Secures Series A Investment of 8.5 Billion Won

Raywatt, a company specializing in cardiovascular medical devices, secured a Series A investment of 8.5 billion won. This investment will help expand business operations and enter global markets.

Key Investment Details

• Amount: 85 billion won
• Investors:
  • Korea Investment Partners
  • IBK Industrial Bank
  • SBI Investment
  • L&S Venture Capital
  • Rein Investment
  • Odstone Investment

Raywatt is actively developing advanced medical technology to enhance cardiovascular health globally. The recent funding highlights the trust investors place in their innovative solutions.

Raywatt’s Innovative Technology

Raywatt has developed the FASTER system, a cutting-edge imaging diagnostic tool. This system achieves high-resolution two-dimensional and three-dimensional imaging in real time. Its main features include:

• Speed: Captures 400 frames per second to scan coronary arteries efficiently.
• Clarity: Provides clear imaging to aid diagnosis.

The system is unique due to its ability to use saline solutions instead of contrast media, reducing patient discomfort and side effects.

Additional Features

• Disposable OCT Catheter (Chouette): Minimizes vibration for stable and accurate vascular scanning.
• AI-based FFR Simulator: Assists in determining stent placement during procedures.

This combination of features sets the FASTER system apart in cardiovascular imaging.

Future Plans and Global Expansion

Raywatt intends to use the investment for:

1. Strengthening research and development.
2. Expanding clinical applications.
3. Accelerating global market entry.

They are currently seeking FDA approval in the United States and pursuing additional international certifications like the CE mark.

Moving Towards Market Leadership

CEO Jin-Yong Ha expressed confidence in Raywatt’s technology and emphasized the goal to lead the cardiovascular diagnostics sector. Raywatt plans to cement its position in the global medical device market with the superior performance of its OCT technology.

Preparation for Public Listing

Raywatt aims for a tech IPO by the end of the next year. To facilitate this, they have appointed Chang-Hoon Han, a former NH Investment & Securities executive, as CFO, signaling a focused push towards public listing readiness.

Conclusion

Raywatt is poised to enhance its impact in the medical device sector with its latest funding. Their commitment to innovation and global reach underscores their potential to become a key player in cardiovascular health technology.

This investment round validates Raywatt’s technological advancements and readiness to scale innovations internationally, driving forward a new era of cardiovascular diagnostics.

Table of Contents:

1. Introduction
   • Overview of Raywatt and its focus on cardiovascular medical devices
   • Significance of securing Series A investment for growth
2. Key Investment Details
   • Breakdown of the investment amount and key investors involved
   • Importance of investor confidence in Raywatt’s innovative solutions
3. Raywatt’s Innovative Technology
   • Introduction to the FASTER system
     • Features and benefits of the imaging diagnostic tool:
       • Speed of capturing images
       • Clarity in imaging for accurate diagnosis
   • Use of saline solutions for reduced patient discomfort
4. Additional Features of the FASTER System
   • Overview of the disposable OCT catheter (Chouette)
   • Introduction to the AI-based FFR simulator and its benefits
5. Future Plans and Global Expansion
   • Strategies for utilizing the investment in research and development
   • Plans for expanding clinical applications and entering international markets
   • Current pursuit of FDA approval and CE mark certifications
6. Moving Towards Market Leadership
   • Insights from CEO Jin-Yong Ha on Raywatt’s ambitions in cardiovascular diagnostics
   • Vision for leading the global medical device market with OCT technology
7. Preparation for Public Listing
   • Overview of plans for a tech IPO
   • Appointment of Chang-Hoon Han as CFO to drive public listing readiness
8. Conclusion
   • Recap of Raywatt’s advancements and their implications for the medical device sector
   • Future outlook on their technology and global market impact